Principal Investigator: Aruna Pradhan, MD, MPH
Study Chair: Paul M Ridker, MD, MPH
The LANCET trial will investigate whether Lantus, a long-acting insulin injection, either alone or in combination with metformin, is effective in reducing C-reactive protein (CRP) in adults with type 2 diabetes. CRP is a marker of chronic low-level inflammation, a new risk factor for diabetes, heart attack, stroke, and other cardiovascular events. Recruitment for this trial is underway.
Send Feedback to: 
